Enterprise Value
70.3M
Cash
142.5M
Avg Qtr Burn
N/A
Short % of Float
29.70%
Insider Ownership
10.43%
Institutional Own.
95.03%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUTIQ Details Chronic non-infectious uveitis | Approved Quarterly sales | |
DEXYCU Details Post-operative inflammation | Approved Quarterly sales | |
EYP-1901 Details Non-proliferative diabetic retinopathy | Phase 2 Data readout | |
EYP-1901 Details Macular degeneration, Wet age-related macular degeneration | Phase 2 Data readout |